H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Palvella Therapeutics (PVLA) to $190 from $95 and keeps a Buy rating on the shares after the company said it is adding QTORIN Pitavastatin as the new product candidate under the QTORIN platform for disseminated superficial actinic porokeratosis. The firm believes that expanding the QTORIN platform beyond Rapamycin to include a statin provides evidence of the breadth and scalability of the platform, the analyst tells investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological Treatments
- Strategic Expansion of Palvella Therapeutics’ QTORIN Platform Targets Unmet Needs in Rare Skin Conditions
- Palvella Therapeutics price target raised to $87 from $80 at Stifel
- Palvella price target raised to $200 from $120 at Cantor Fitzgerald
- Palvella Therapeutics Unveils QTORIN™ Pitavastatin for DSAP